Pharmaceutical Deal Trends 2017 Factbook: Partnerships and Acquisitions Shift Focus Towards Early Stage Development, Emerging Markets, and Biologics
Summary Pharmaceutical market is continuing to see global growth, whereas pharmaceutical and biotechnology companies are facing challenges due to disruptive events in the healthcare market such as increasing costs of production and R&D, shifts in patent laws, and challenges in the economy. Companies are considering various strategies to overcome the current challenges, with deal making being foremost among these as a means of boosting revenues over a short period of time.
Agreements between companies for drug discovery, which allow them to share the risk of co-developing products, have become more common. Small companies that primarily carry out early-stage research, development and production activities are entering into agreements with key industry leaders to out-license the rights to their products, utilizing the strengths of the larger companies in terms of commercialization expertise, manufacturing, distribution and marketing capabilities and global presence.
Meanwhile, key players keen to secure novel and promising molecules are willing to co-operate with small players to in-license promising early-stage assets to expand their portfolios, reduce R&D risks and move ahead in the market. Also, therapies have historically been manufactured in a one-size-fits-all approach for chronic diseases, among other therapy areas. Recently, a more personalized approach is being chosen by pharmaceutical companies, which are increasing the development of targeted therapies even for rare diseases.
The report "Pharmaceutical Deal Trends 2017 Factbook: Partnerships and Acquisitions Shift Focus Towards Early Stage Development, Emerging Markets, and Biologics" analyzes the importance of deal making in the pharmaceutical and healthcare market. There were a total of 2,028 deals made in 2016, with an aggregate deal value of $189 billion. Deal activity has a very wide range of purposes, including helping pharma companies to enhance their research and regulatory approaches, and aiding portfolio expansion and diversification, geographic expansion, entry into niche markets, commercialization, and sales.
Specifically, this report provides the following -
- Covers key factors that encourage deal activity in the pharmaceutical industry, and the key strategies being implemented when companies strike deals. These strategies can be utilized for a variety of purposes, including solidifying market presence, averting revenue losses due to key product patent expiries, increasing R&D potential and output, and expanding a company’s operations, products and overall presence in various geographies. - An overview of recent deal activity from 2010 to May 2017 is provided. It covers - - Number of deals and aggregate deal values - Trends in deals by geography and major therapy area - Trends in products involved in deals, based on molecule type, stage of development and type of deal - Discusses key companies involved in deal making over recent years (2012–2016), and their recent key deal activity is analyzed. - Recently announced M&As, licensing deals and partnership deals that took place between 2016 and Q1 2017 are analyzed.
Companies mentioned in this report: Pfizer, Merck, Bayer, Allergan, Valeant.
Scope - What deal making strategies have been used in recent years to boost R&D productivity and allow the successful commercialization of pharmaceutical products? - In which geographical markets and disease areas has deal activity been focused since 2010? - At which stage of development did deals most frequently occur, and attract the highest value? - How have pharma companies been using deal making to strengthen their product portfolio and bottom line? - What are the most significant Mergers and Acquisitions (M&As), licensing deals and partnership deals to have been announced since 2016? - Who are the major players in pharmaceutical deal making, and what has been their recent and key deal activity?
Key Reasons to Purchase - Gain a comprehensive understanding of the most recent healthcare deal trends. - Understand the most significant M&As, licensing deals and partnerships to have occurred in recent years. - Comprehensively analyze the trends of deal activity from 2010 to May 2017, with respect to aggregate deal value, geography, and the therapy area and stage of development of the products involved. - Understand the deal-making strategies that have been historically implemented by companies, and identify the most suitable strategies for boosting R&D portfolio and bottom line performance. - Identify the key deal terminations that have occurred in recent years, and understand their effect.
Our reports have been used by over 10K customers, including:
Retinoic Acid Receptor Gamma - Drugs In Development, 2021 Summary Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Retinoic acid receptor gamma (RARG) is a nuclear receptor that is encoded by the RARG gene. RARG bind as heterodimers to the...
175 pages •
By The Business Research Company
• Sep 2021
Major players in the desiccants market are Porocel, The Dow Chemical, INEOS, Fuji Silysia Chemical, and Hengye Molecular Sieve. The global desiccants market is expected to grow from $0.13 billion in 2020 to $0.14 billion in 2021 at a compound annual growth rate (CAGR) of 7.7%. The growth is mainly due to the companies resuming their...
Glucose Dependent Insulinotropic Receptor - Drugs In Development, 2021 Summary Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - G protein-coupled receptor 119 also known as GPR119 is a G protein-coupled receptor that is encoded by the GPR119 gene. GPR119 is expressed...
Global Big Pharma Partnering Terms and Agreements 2014 to 2021 report provides a detailed understanding and analysis of how and why companies enter Big Pharma partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes. This report provides...
Global Specialty Pharmaceutical Partnering Terms and Agreements 2014 to 2021 report provides a detailed understanding and analysis of how and why companies enter Specialty Pharmaceutical partnering deals. This report provides details of the latest Specialty Pharmaceutical agreements announced in the life sciences since...
The analyst presents post-COVID-19 growth opportunities and strategic imperatives for the global drug discovery and early development outsourcing market in this study, which covers research and development (R&D) efforts, market trends, key participants, drivers and restraints of market adoption, and recent mergers and acquisitions. The report...
The thermal pallet covers market was valued at US$ 4,599.65 million in 2021 and is projected to reach US$ 10,469.73 million by 2028; it is expected to grow at a CAGR of 12.5% from 2021 to 2028. Thermal pallet covers safeguard temperature-sensitive goods from the effects of harsh weather and decrease the risk of excursions.The heat transmission...
Heparanase - Drugs In Development, 2021 Summary Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 22.214.171.124) pipeline Target constitutes close to 15 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The latest report...
Nociceptin Receptor - Drugs In Development, 2021 Summary According to the recently published report ’Nociceptin Receptor - Drugs In Development, 2021’; Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) pipeline Target constitutes close to 14 molecules. Out...
Alcohol Excessive Use
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.